Mirum Pharmaceuticals Price To Sales vs. Cash And Equivalents

MIRM Stock  USD 46.22  0.43  0.92%   
Based on Mirum Pharmaceuticals' profitability indicators, Mirum Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Mirum Pharmaceuticals' ability to earn profits and add value for shareholders.

Mirum Pharmaceuticals Price To Sales Ratio

6.15

As of the 30th of November 2024, Sales General And Administrative To Revenue is likely to grow to 1.49, while Price To Sales Ratio is likely to drop 6.15. At this time, Mirum Pharmaceuticals' Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 30th of November 2024, Interest Income is likely to grow to about 12.7 M, though Net Loss is likely to grow to (156 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.910.7476
Fairly Up
Slightly volatile
For Mirum Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mirum Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mirum Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mirum Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mirum Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Mirum Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Correlation Analysis.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
6.513
Quarterly Revenue Growth
0.894
Return On Assets
(0.09)
Return On Equity
(0.40)
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Mirum Pharmaceuticals Cash And Equivalents vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Mirum Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Mirum Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Mirum Pharmaceuticals is rated below average in price to sales category among its peers. It is rated below average in cash and equivalents category among its peers creating about  17,290,289  of Cash And Equivalents per Price To Sales. At this time, Mirum Pharmaceuticals' Price To Sales Ratio is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mirum Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Mirum Cash And Equivalents vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Mirum Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
7.23 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Mirum Pharmaceuticals

Cash

 = 

Bank Deposits

+

Liquidities

 = 
124.95 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Mirum Cash And Equivalents Comparison

Mirum Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Mirum Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Mirum Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mirum Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Mirum Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Mirum Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.6 M1.7 M
Interest Income12.1 M12.7 M
Operating Income-109.2 M-114.6 M
Net Loss-164.2 M-156 M
Income Before Tax-162.4 M-154.3 M
Non Operating Income Net Other4.9 M5.1 M
Total Other Income Expense Net-53.3 M-50.6 M
Net Loss-122.1 M-128.2 M
Net Loss-163.4 M-155.2 M
Income Tax Expense991 KM
Net Interest Income-3.8 M-4 M
Change To Netincome31.1 M19.8 M
Net Loss(4.00)(4.20)
Income Quality 0.43  0.61 
Net Income Per E B T 1.01  1.09 

Mirum Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Mirum Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mirum Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mirum Pharmaceuticals' important profitability drivers and their relationship over time.

Use Mirum Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mirum Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mirum Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Mirum Pharmaceuticals Pair Trading

Mirum Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Mirum Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mirum Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mirum Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mirum Pharmaceuticals to buy it.
The correlation of Mirum Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mirum Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mirum Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mirum Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Mirum Pharmaceuticals position

In addition to having Mirum Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Defence Thematic Idea Now

Aggressive Defence
Aggressive Defence Theme
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
Check out Correlation Analysis.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
To fully project Mirum Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Mirum Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Mirum Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Mirum Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Mirum Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Mirum Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mirum Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.